Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
– Positive Phase 3 Results from Both ARTISTRY-2 and ARTISTRY-1 Trials will Form the Basis of Regulatory Submissions – FOSTER CITY, Calif., December 15, 2025 BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from BIKTARVY ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to a fixed-dose combination of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically non-inferior to BIKTARVY. Gilead plans to file the Phase 3 results from the ARTISTRY trials with regulatory authorities and submit the detailed findings for presentation at a future scientific congress. In ARTISTRY-2, the once-daily single tablet regimen of BIC/LEN met the primary success criterion for non-inferiority to BIKTARVY. The primary efficacy endpoin
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 TrialBusiness Wire
- Gilead Sciences (NASDAQ:GILD) had its "outperform" rating reaffirmed by analysts at Wolfe Research.MarketBeat
- Is Earlier Yescarta Use in Lymphoma Altering The Investment Case For Gilead Sciences (GILD)? [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Morgan Stanley from $147.00 to $151.00. They now have an "overweight" rating on the stock.MarketBeat
- Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD) [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 12/15/25 - Form 144
- 12/15/25 - Form 144
- 12/11/25 - Form 4
- GILD's page on the SEC website